High Dose Ifosfamide in Relapsed and Unresectable High-Grade Osteosarcoma Patients: A Retrospective Series
Open accessAbstract
Background: The evidence on high-dose ifosfamide (HD-IFO) use in patients with relapsed osteosarcoma is limited. We performed a retrospective study to analyze HD-IFO activity. Methods: Patients with osteosarcoma relapsed after standard treatment [methotrexate, doxorubicin, cisplatin +/− ifosfamide (MAP+/−I)] with measurable disease according to RECIST1.1 were eligible to ifosfamide (3 g/m2/day) continuous infusion (c.i.) days 1–5 q21d. RECIST1.1 overall response rate (ORR) (complete response (CR) + partial response (PR)), progression-free survival at 6-month (6m-PFS), duration of response (DOR), and 2-year overall survival (2y-OS) were assessed. PARP1 expression and gene mutations were tested by immunohistochemistry and next-generation sequencing. Results: 51 patients were included. ORR was 20% (1 CR + 9 PR). Median DOR was 5 months (95%CI 2–7). Median PFS, 6m-PFS, OS, and 2y-OS were 6 months (95%CI 4–9), 51%, 15 months (10–19), and 30%, respectively. A second surgical complete remission (CR2) was achieved in 26 (51%) patients. After multivariate analysis, previous use of ifosfamide (HR 2.007, p = 0.034) and CR2 (HR 0.126, p < 0.001) showed a significant correlation with PFS and OS, respectively. No significant correlation was found between outcomes and PARP1 or gene mutations. Conclusions: HD-IFO should be considered as the standard first-line treatment option in relapsed osteosarcoma and control arm of future trial in this setting.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Systemic treatment for advanced bone sarcoma progressing after upfront chemotherapy is challenging, with best results still leveraging ifosfamide for Ewing sarcoma and osteosarcoma, whereas evidence is limited in dedifferentiated chondrosarcoma, conventional chondrosarcoma, and other ultra-rare bone sarcomas.
“Systemic treatment for advanced bone sarcoma (BS) progressing after upfront chemotherapy is challenging, with best results still leveraging on the use of ifosfamide both for Ewing sarcoma 1 and osteosarcoma, 2 , 3 whereas evidence is limited in dedifferentiated chondrosarcoma (DDCS), 4 conventional chondrosarcoma 5 and other ultra‐rare BS. 6”
From Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single‐arm, phase 2 trial (2025) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bielack, S. S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.776 · Cited by 2,393 · see citing works
Bielack, S., Kempf-Bielack, B., Delling, G., Exner, G. U., Flege, S., Helmke, K., Kotz, R., Salzer-Kuntschik, M., Werner, M., Winkelmann, W., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.776 · Cited by 2,391 · see citing works
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643 · see citing works
Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy310 · Cited by 617 · see citing works
Self-citationMarina, N. M., Smeland, S., Bielack, S. S., Bernstein, M., Jovic, G., Krailo, M. D., Hook, J. M., Arndt, C., van den Berg, H., Brennan, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30214-5 · Cited by 551 · see citing works
Gnanasegaran, G., Cook, G., Vijayanathan, S., & Fogelman, I. (2007) · CRC Press eBooks · doi:10.3109/9781420091380-19 · Cited by 468 · see citing works
Grignani, G., Palmerini, E., Dileo, P., Asaftei, S. D., D’Ambrosio, L., Pignochino, Y., Mercuri, M., Picci, P., Fagioli, F., Casali, P. G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr151 · Cited by 359 · see citing works
Self-citationDuffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E., Delcambre, C., Kalbacher, E., Italiano, A., Collard, O., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30742-3 · Cited by 331 · see citing works
Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E., Chevreau, C., Duffaud, F., Entz-Werlé, N., Saada, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30825-3 · Cited by 326 · see citing works
Miser, J. S., Kinsella, T. J., Triche, T. J., Tsokos, M., Jarosinski, P., Forquer, R., Wesley, R., & Magrath, I. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.8.1191 · Cited by 317 · see citing works
Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival
Ferrari, S., Briccoli, A., Mercuri, M., Bertoni, F., Picci, P., Tienghi, A., Del Prever, A. B., Fagioli, F., Comandone, A., & Bacci, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.141 · Cited by 316 · see citing works
Self-citationRandomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Davis, L. E., Bolejack, V., Ryan, C. W., Ganjoo, K. N., Loggers, E. T., Chawla, S., Agulnik, M., Livingston, M. B., Reed, D., Keedy, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02374 · Cited by 268 · see citing works
PATEL, S. R., Vadhan‐Raj, S., Papadopolous, N., Plager, C., Burgess, M. A., Hays, C., & Benjamin, R. S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2378 · Cited by 257 · see citing works
Pelgrims, J., Vos, F. D., den Brande, J. V., Schrijvers, D. M., Prové, A., & Vermorken, J. B. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0917 · Cited by 244 · see citing works
Campanacci, M. (1999) · Springer eBooks · doi:10.1007/978-3-7091-3846-5 · Cited by 230 · see citing works
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma
Ferrari, S., & Palmerini, E. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328122d73f · Cited by 220 · see citing works
Self-citationCesne, A. L., Antoine, É.-C., Spielmann, M., Chevalier, T. L., Brain, E. G. C., Toussaint, C., Janin, N., Kayitalire, L., Fontaine, F., & Génin, J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1600 · Cited by 206 · see citing works
Navid, F., Willert, J. R., McCarville, M. B., Furman, W. L., Watkins, A., Roberts, W., & Daw, N. C. (2008) · Cancer · doi:10.1002/cncr.23586 · Cited by 153 · see citing works
Treatment of osteosarcoma at first recurrence after contemporary therapy
Chou, A. J., Merola, P. R., Wexler, L. H., Gorlick, R. G., Vyas, Y. M., Healey, J. H., LaQuaglia, M. P., Huvos, A. G., & Meyers, P. A. (2005) · Cancer · doi:10.1002/cncr.21417 · Cited by 132 · see citing works
Fox, E., PATEL, S. R., Wathen, J. K., Schuetze, S. M., Chawla, S. P., Harmon, D. C., Reinke, D. K., Chugh, R. K., Benjamin, R. S., & Helman, L. J. (2012) · The Oncologist · doi:10.1634/theoncologist.2010-0265 · Cited by 120 · see citing works
Harris, M. B., Cantor, A. B., Goorin, A. M., Shochat, S. J., Ayala, A. G., Ferguson, W. S., Holbrook, T., & Link, M. P. (1995) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950240205 · Cited by 110 · see citing works
Palmerini, E., Jones, R. L., Marchesi, E., Paioli, A., Cesari, M., Longhi, A., Meazza, C., Coccoli, L., Fagioli, F., Asaftei, S., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2312-3 · Cited by 98 · see citing works
Self-citationGrignani, G., D’Ambrosio, L., Pignochino, Y., Palmerini, E., Zucchetti, M., Boccone, P., Aliberti, S., Stacchiotti, S., Bertulli, R., Piana, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30438-8 · Cited by 93 · see citing works
Self-citationPignochino, Y., Capozzi, F., D’Ambrosio, L., Dell’Aglio, C., Basiricò, M., Canta, M., Lorenzato, A., Lutati, F. V., Aliberti, S., Palesandro, E., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0652-5 · Cited by 70 · see citing works
Self-citationBerger, M., Grignani, G., Ferrari, S., Biasin, E., Adalberto, B. D. P., Sandra, A., Saglio, F., Aglietta, M., & Franca, F. (2009) · Cancer · doi:10.1002/cncr.24368 · Cited by 61 · see citing works
Self-citationHigh‐dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity
Berrak, S. G., Pearson, M. G., Berberoĝlu, S., İlhan, İ. E., & Jaffe, N. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.20228 · Cited by 58 · see citing works
Song, B. S., Seo, J., Kim, D. H., Lim, J. S., Yoo, J. Y., & Lee, J. A. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25035 · Cited by 57 · see citing works
Lønning, P. E., & Knappskog, S. (2013) · Oncogene · doi:10.1038/onc.2013.48 · Cited by 53 · see citing works
Treatment of Refractory Osteosarcoma With Fractionated Cyclophosphamide and Etoposide
Rodríguez-Galindo, C., Daw, N. C., Kaste, S. C., Meyer, W. H., Dome, J. S., Pappo, A. S., Rao, B. N., & Pratt, C. B. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200205000-00006 · Cited by 40 · see citing works
Bertucci, F., Finetti, P., Monneur, A., Perrot, D., Chevreau, C., Cesne, A. L., Blay, J., Mir, O., & Birnbaum, D. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12522 · Cited by 23 · see citing works
Therapeutic Implication of Genomic Landscape of Adult Metastatic Sarcoma
Feng, X., Pleasance, E., Stutheit-Zhao, E. Y., Ng, T., Grewal, J., Mohammad, N., Taylor, S. K., Simmons, C. E., Srikanthan, A., Rassekh, S. R., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00325 · Cited by 21 · see citing works
Verschoor, A. J., Speetjens, F. M., Dijkstra, P. D. S., Fiocco, M. F., van de Sande, M. A. J., Bovée, J. V. M. G., & Gelderblom, H. A. J. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0528 · Cited by 12 · see citing works
Ferrari, S., Zolezzi, C., Cesari, M., Fasano, M., Lamanna, G., & Bacci, G. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199901000-00004 · Cited by 12 · see citing works
Self-citationGaspar, N., Sirvent, F. J. B., Venkatramani, R., Longhi, A., Lervat, C., Casanova, M., Aerts, I., Bielack, S., Entz‐Werlé, N., Strauss, S. J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz283.009 · Cited by 9 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Future Directions in the Treatment of Osteosarcoma
Smrke, A., Anderson, P. M., Gulia, A., Gennatas, S., Huang, P. H., & Jones, R. L. (2021) · Cells · doi:10.3390/cells10010172 · Cited by 225 · see citing works
Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies
Hattinger, C. M., Patrizio, M. P., Fantoni, L., Casotti, C., Riganti, C., & Serra, M. (2021) · Cancers · doi:10.3390/cancers13122878 · Cited by 110 · see citing works
Demetri, G. D., Luke, J. J., Hollebecque, A., Powderly, J. D., Spira, A. I., Subbiah, V., Naumovski, L., Chen, C., Fang, H. A., Lai, D. W., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4513 · Cited by 87 · see citing works
SELNET clinical practice guidelines for bone sarcoma
Blay, J., Palmerini, E., Bollard, J., Aguiar, S., Angel, M. O., Araya, B. B., Badilla, R., Bernabéu, D., Campos, F. A. B., Caro-Sánchez, C. H. S., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103685 · Cited by 34 · see citing works
Self-citationPastorino, U., Palmerini, E., Porcu, L., Luksch, R., Scanagatta, P., Meazza, C., Leuzzi, G., Massimino, M., & Picci, P. (2021) · Tumori Journal · doi:10.1177/03008916211053048 · Cited by 33 · see citing works
Self-citationvan Ewijk, R., Herold, N., Baecklund, F., Baumhoer, D., Boye, K., Gaspar, N., Harrabi, S., Haveman, L., Hecker‐Nolting, S., Hiemcke‐Jiwa, L. S., et al. (2023) · EJC Paediatric Oncology · doi:10.1016/j.ejcped.2023.100029 · Cited by 30 · see citing works
Self-citationPalmerini, E., Lopez Pousa, A., Grignani, G., Redondo, A., Hindi, N., Provenzano, S., Sebio, A., Lopez Martin, J. A., Valverde, C., Martinez Trufero, J., et al. (2025) · Cancer · doi:10.1002/cncr.35628 · Cited by 29 · see citing works
“…after upfront chemotherapy is challenging, with best results still leveraging on the use of ifosfamide both for Ewing sarcoma 1 and osteosarcoma, 2,3 whereas evidence is limited in dedifferentiated chondrosarcoma (DDCS), 4 conventional chondrosarcoma 5 and other ultra ‐ rare BS. 6 Addressing…”
Self-citationState-of-the-art, approved therapeutics for the pharmacological management of osteosarcoma
Meazza, C., & Asaftei, S. D. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1936499 · Cited by 29 · see citing works
Current approaches to management of bone sarcoma in adolescent and young adult patients
Ingley, K. M., Maleddu, A., Grange, F. L., Gerrand, C., Bleyer, A., Yasmin, E., Whelan, J. S., & Strauss, S. J. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29442 · Cited by 26 · see citing works
Vari, S., Riva, F., Onesti, C. E., Cosimati, A., Renna, D., Biagini, R., Baldi, J., Zoccali, C., Anelli, V., Annovazzi, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810721 · Cited by 25 · see citing works
Martins‐Neves, S. R., Sampaio-Ribeiro, G., & Gomes, C. M. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911416 · Cited by 21 · see citing works
van Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19 · see citing works
Self-citationWatanabe, M., Nakai, H., Ohara, T., Kawasaki, K., Murosaki, S., & Hirose, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-62657-0 · Cited by 16 · see citing works
Investigation of Ifosfamide Toxicity Induces Common Upstream Regulator in Liver and Kidney
Han, H., Choi, M., Yoon, S., Ko, J., Kim, S. K., & Kim, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212201 · Cited by 14 · see citing works
Carter, T. J., Milić, M., McDerra, J., McTiernan, A., Ahmed, M., Karavasilis, V., Michelagnoli, M. P., Windsor, R. E., Seddon, B. M., Whelan, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12113408 · Cited by 12 · see citing works
Saji, R., Uchio, R., Fuwa, A., Okuda-Hanafusa, C., KAWASAKI, K., Muroyama, K., Murosaki, S., Yamamoto, Y., & Hirose, Y. (2023) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.2022-071 · Cited by 10 · see citing works
Tirtei, E., Campello, A., Sciannameo, V., Asaftei, S. D., Meazza, C., Sironi, G., Longhi, A., Ibrahim, T., Tamburini, A., Coccoli, L., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12498-x · Cited by 10 · see citing works
Self-citationWu, H., He, Z., Li, X., Xu, X., Zhong, W., Bu, J., & Huang, G. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.690409 · Cited by 9 · see citing works
Huang, J., Cheng, J., Bi, W., Xu, M., Jia, J., Han, G., & Wang, W. (2022) · Orthopaedic Surgery · doi:10.1111/os.13563 · Cited by 9 · see citing works
MicroRNA signatures in osteosarcoma: diagnostic insights and therapeutic prospects
Dey, M., Skipar, P., Bartnik, E., Piątkowski, J., Sulejczak, D., & Czarnecka, A. M. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05135-5 · Cited by 8 · see citing works
Yoo, S., Mun, Y., Kang, N.-W., Koo, J. M., Lee, D. H., Yoo, J. H., Lee, S. M., Koh, S., Park, J. C., Kim, T. J., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10472 · Cited by 7 · see citing works
Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review
Rubio‐San‐Simón, A., Wilson, W., Sironi, G., Deley, M. L., Palmerini, E., Gaspar, N., Piperno-Neumann, S., Hecker‐Nolting, S., Strauss, S. J., van Ewijk, R., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03118-x · Cited by 4 · see citing works
Self-citationEngineered biomaterial delivery strategies are used to reduce cardiotoxicity in osteosarcoma
Hou, Y., Wang, J., & Wang, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1284406 · Cited by 4 · see citing works
Osteogenic Sarcoma of the Head and Neck: Is Chemotherapy Needed?
Bialick, S., Campoverde, L., Gallegos, J. A. O., Barreto‐Coelho, P., Watson, A., Arora, K. S., Perez, A. R., Lopez, E., Venkat, S. R., Rosenberg, A. E., et al. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01073-4 · Cited by 4 · see citing works
Huang, G., Hua, S., Liu, H., Zhou, H., Chen, X., Wang, Z., & Yu, W. (2022) · PubMed Central · Cited by 4 · see citing works
Silva, J. A., Gunasinghe, K., Jonus, H. C., Branella, G. M., Bustamante, A. Y. S., Okáľová, J., Yustein, J. T., & Spencer, H. T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1657760 · Cited by 3 · see citing works
Hoberger, M., Zuber, R. L., Burkhard‐Meier, A., Gioia, D. D., Jurinović, V., Völkl, M., Güler, S. E., Albertsmeier, M., Klein, A., Dürr, H. R., et al. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06410-8 · Cited by 1 · see citing works
Novel agents in a young patient with osteosarcoma: A short review
Steinbrecher, O., Brodowicz, T., & Lamm, W. W. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00728-y · Cited by 1 · see citing works
The Effect of Ifosfamide and Mifamurtide Loaded Cement on The Viability of Osteosarcoma Cells
Bekçioğlu, Ö., Aktaş, S., Aydın, M., & Olgun, N. (2021) · Turkish Journal of Hip Surgery · doi:10.5505/tjhs.2021.76486
(2020) · Reactions Weekly · doi:10.1007/s40278-020-87321-5
Riva, F., Vari, S., Onesti, C. E., Covello, R., Scuderi, S., Ceddia, S., Fiore, M. R., Anelli, V., Strippoli, S., & Ferraresi, V. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1604056
Tirtei, E., Campello, A., Sciannameo, V., Asaftei, S. D., Meazza, C., Sironi, G., Longhi, A., Ibrahim, T., Tamburini, A., Coccoli, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26066128
Self-citationMascagni, I., Laffi, A., Grimaudo, M. S., Cananzi, F., Samà, L., Renne, S. L., D’Orazio, F., Navarria, P., Clerici, E., Carnaghi, C., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.71614
Burke, Z. D. C., Lin‐Rahardja, K., Mandel, G., Imamura, J., Durmaz, A., Nowak, E., Hitomi, M., & Scott, J. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.10.743977
When the Cure Runs Out: The Ifosphamide Shortage and Its Silent Toll on Children With Cancer
Prasad, P. K. (2026) · Pediatric Blood & Cancer · doi:10.1002/1545-5017.70680
Hashim, N. M., & Hapidin, H. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120235
- Authors
- Palmerini, E., Setola, E., Grignani, G., D’Ambrosio, L., Comandone, A., Righi, A., Longhi, A., Cesari, M., Paioli, A., Hakim, R., Pierini, M., Marchesi, E., Vanel, D., Pignochino, Y., Donati, D. M., Picci, P., & Ferrari, S.
- Affiliations
- Istituto Ortopedico Rizzoli (IT)
- Candiolo Cancer Institute (IT)
- Ospedale San Giovanni Bosco (IT)
- Italian Sarcoma Group (IT)
- Orthopedic Oncology, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
- Corresponding author
- D’Ambrosio, Lorenzo
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-10-31
- Volume
- 9
- Issue
- 11
- Pages
- 2389
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC7692098
- OpenAlex
- W3096639263
- Cited by
- 36
- References
- 34
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 6 · 2021: 10 · 2020: 2
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Commission
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
- Health Sciences › Medicine › Rheumatology › Bone Tumor Diagnosis and Treatments
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Keywords
- high-dose ifosfamide, relapsed osteosarcoma, continuous infusion chemotherapy, overall response rate, progression-free survival, overall survival, genetic mutations
- MeSH terms
- Poly (ADP-Ribose) Polymerase-1, Adolescent, Adult, Aged, Bone Neoplasms, Child, Cisplatin, Dose-Response Relationship, Drug, Doxorubicin, Female, Humans, Ifosfamide, Male, Methotrexate, Middle Aged, Mutation, Neoplasm Recurrence, Local, Retrospective Studies, Osteosarcoma, Treatment Outcome, Young Adult, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
